Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.Molnupiravir (Drug), Coronavirus (2019-nCoV), Gates, Bill and Melinda, Foundation, International Trade and World Market, Drugs (Pharmaceuticals), Merck & Company IncRead More
